Immune checkpoint blockade for the treatment of Hodgkin lymphoma
Classical Hodgkin lymphoma is biologically different than other lymphomas. The cancer
cells only occupy a small amount of the lymph node and evade the immune system by …
cells only occupy a small amount of the lymph node and evade the immune system by …
Efficacy and safety of immune checkpoint inhibitors in hematologic malignancies
The emergence of immune checkpoint inhibitors (ICIs) has led to a dramatic paradigm shift
within the landscape of cancer treatment, igniting significant interest in their potential …
within the landscape of cancer treatment, igniting significant interest in their potential …
Targeting tumour-associated macrophages in hodgkin lymphoma using engineered extracellular matrix-mimicking cryogels
Tumour-associated macrophages are linked with poor prognosis and resistance to therapy
in Hodgkin lymphoma; however, there are no suitable preclinical models to identify …
in Hodgkin lymphoma; however, there are no suitable preclinical models to identify …
Facile preparation of a metal-phenolic network-based lymph node targeting nanovaccine for antitumor immunotherapy
Q Su, Z Liu, R Du, X Chen, L Chen, Z Fu, X Luo… - Acta Biomaterialia, 2023 - Elsevier
Cancer vaccines are being explored for enhanced cancer immunotherapy and prophylaxis.
Some of their prevailing weaknesses, however, such as complicated preparation, poor …
Some of their prevailing weaknesses, however, such as complicated preparation, poor …
A combination of cytokine-induced killer cells with PD-1 blockade and ALK inhibitor showed substantial intrinsic variability across non-small cell lung cancer cell lines
Y Li, A Sharma, X Wu, H Weiher, D Skowasch… - Frontiers in …, 2022 - frontiersin.org
Background Cancer heterogeneity poses a serious challenge concerning the toxicity and
adverse effects of therapeutic inhibitors, especially when it comes to combinatorial therapies …
adverse effects of therapeutic inhibitors, especially when it comes to combinatorial therapies …
Resistance mechanisms to programmed cell death protein 1 and programmed death ligand 1 inhibitors
PS Pezeshki, P Mahdavi Sharif… - Expert Opinion on …, 2021 - Taylor & Francis
Introduction: In the past few years, administrating monoclonal humanized antibodies,
namely checkpoint inhibitors, against programmed cell death protein 1 (PD-1), and its ligand …
namely checkpoint inhibitors, against programmed cell death protein 1 (PD-1), and its ligand …
[HTML][HTML] Protocol: Monitoring multidimensional aspects of quality of life after cancer immunotherapy: protocol for the international multicentre, observational QUALITOP …
Introduction Immunotherapies, such as immune checkpoint inhibitors and chimeric antigen
receptor T-cell therapy, have significantly improved the clinical outcomes of various …
receptor T-cell therapy, have significantly improved the clinical outcomes of various …
Monitoring multidimensional aspects of quality of life after cancer immunotherapy: protocol for the international multicentre, observational QUALITOP cohort study
Introduction Immunotherapies, such as immune checkpoint inhibitors and chimeric antigen
receptor T-cell therapy, have significantly improved the clinical outcomes of various …
receptor T-cell therapy, have significantly improved the clinical outcomes of various …
[HTML][HTML] The Outcome of Hodgkin Lymphoma With Reference to Prognostic Markers
R Ahmed, F Tariq, J Ashfaq, W Thakur, S Zafar… - Cureus, 2022 - ncbi.nlm.nih.gov
Objectives: This study aimed to determine the impact of prognostic markers on the outcomes
of Hodgkin lymphoma. Methods: It is a cross-sectional, single-center study. A total of 60 …
of Hodgkin lymphoma. Methods: It is a cross-sectional, single-center study. A total of 60 …
Immune Checkpoints and targeted agents in relapse and graft-versus-host disease after hematopoietic stem cell transplantation
J Zhu, J Chen - Molecular Biology Reports, 2023 - Springer
Background: Allogeneic hematopoietic stem cell transplantation (HSCT) is a potentially
curative therapy for malignant hematologic disorders. Novel anti-infection agents have …
curative therapy for malignant hematologic disorders. Novel anti-infection agents have …